Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2015 - 2026)

Avalo Therapeutics has reported Total Non-Current Liabilities for 12 years, with the latest figure at $31.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 286.45% year-over-year to $31.6 million; the trailing twelve-month figure through Mar 2026 stood at $31.6 million (up 286.45% YoY), and the FY2025 full-year result was $15.4 million, up 60.85% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $31.6 million, up from $15.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $223.5 million in Q1 2024, with the low at $8.2 million in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $45.0 million across 5 years, with a median of $33.4 million in 2025.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 564.01% — and 2025, when it sank 96.35%.
• Avalo Therapeutics' Total Non-Current Liabilities stood at $42.6 million in 2022, then slumped by 71.05% to $12.3 million in 2023, then retreated by 22.26% to $9.6 million in 2024, then jumped by 60.85% to $15.4 million in 2025, then jumped by 104.85% to $31.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $31.6 million (Q1 2026), $15.4 million (Q4 2025), and $33.4 million (Q3 2025), per Business Quant data.